glp 1 anorexia nervosa Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society - Novel potential pharmacological approaches in
Description
Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant weight loss and ACR50 disease control in adults with active psoriatic arthritis (PsA).
Editorial Disclosure:Our clinical reviews are independent and science-led
The supplier who manufactures your drug
A top weight loss doctor reveals how to maximize your results and reach your goals.
Learn more about GPCR stock here.
17+ years of medical weight loss experience, labs, and protocol-driven.
